Yahong Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yahong Zhou has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Xue Li
Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine Wuxi Jiangsu China
3 shared publicationsFan Jia
Institute of Traditional Chinese Medicine, Wuxi Affiliated Hospital of Nanjing University of Chinese Medicine, Wuxi, China
2 shared publicationsHang Zhang
College of Animal Science and Technology, College of Animal Medicine Huazhong Agricultural University Wuhan Hubei China
2 shared publications- Hong Wei
Precision Medicine Institute, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, P. R. China
2 shared publications Lin Zhao
Jiangnan Univ, Affiliated Hosp, Dept Gastroenterol, 1000 Hefeng Rd, Wuxi 214000, Peoples R China
2 shared publications- Yuzheng Xue
Department of Gastroenterology, Affiliated Hospital of Jiangnan University, Wuxi 214122, China
2 shared publications
Latest Publications
- Open Access
- 5 November 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1614165
A reverse network pharmacology and bioinformatics-based approach to exploring medication patterns for polycystic ovary syndrome-related infertility
Objective: To predict potential herbal medicines targeting polycystic ovary syndrome (PCOS)-related infertility using an in silico reverse network pharmacology approach and identify core herbal candidates. Methods: This computational study began by collecting disease targets for PCOS and infertility from multiple public databases. Common targets were identified, and active compounds associated with these targets were retrieved from the Uniprot and TCMSP databases. These compounds were subsequently filtered using PubChem and SwissADME based on pharmacokinetic properties and mapped to corresponding herbs via TCMSP. Herbal properties (nature, flavor, meridian tropism) were statistically analyzed. A core network of targets-compounds-herbs was constructed using Cytoscape 3.8.0, and a subnetwork was generated from nodes with a Degree > 20. Finally, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed on the targets of the core herbal combination to elucidate potential mechanisms. Results: A total of 2,500 common targets for PCOS and infertility, 1,545 active compounds, and 488 corresponding herbs were identified. Analysis of herbal properties revealed a predominance of Warm and Pungent medicines, followed by Cold, Bitter, Neutral, and Sweet medicines. A core herbal combination consisting of Ephedra sinica (Mahuang), Magnolia officinalis (Houpo), Bupleurum chinense (Chaihu), Chrysanthemum morifolium (Juhua), Angelica dahurica (Baizhi), and Morus alba (Sangye) was identified through frequency statistics, association rules, and cluster analysis. GO and KEGG enrichment analyses of the core combination’s targets highlighted mechanisms involving oxidative stress, inflammatory responses, and endocrine regulation, including the TNF and PI3K-Akt signaling pathways. Conclusion: This study successfully employed reverse network pharmacology to predict a core herbal combination for treating PCOS-related infertility. The findings, while requiring experimental validation, offer novel insights for developing therapeutic strategies and provide a foundation for future clinical management.
- 5 November 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1614165
Open AccessA reverse network pharmacology and bioinformatics-based approach to exploring medication patterns for polycystic ovary syndrome-related infertility
Objective: To predict potential herbal medicines targeting polycystic ovary syndrome (PCOS)-related infertility using an in silico reverse network pharmacology approach and identify core herbal candidates. Methods: This computational study began by collecting disease targets for PCOS and infertility from multiple public databases. Common targets were identified, and active compounds associated with these targets were retrieved from the Uniprot and TCMSP databases. These compounds were subsequently filtered using PubChem and SwissADME based on pharmacokinetic properties and mapped to corresponding herbs via TCMSP. Herbal properties (nature, flavor, meridian tropism) were statistically analyzed. A core network of targets-compounds-herbs was constructed using Cytoscape 3.8.0, and a subnetwork was generated from nodes with a Degree > 20. Finally, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed on the targets of the core herbal combination to elucidate potential mechanisms. Results: A total of 2,500 common targets for PCOS and infertility, 1,545 active compounds, and 488 corresponding herbs were identified. Analysis of herbal properties revealed a predominance of Warm and Pungent medicines, followed by Cold, Bitter, Neutral, and Sweet medicines. A core herbal combination consisting of Ephedra sinica (Mahuang), Magnolia officinalis (Houpo), Bupleurum chinense (Chaihu), Chrysanthemum morifolium (Juhua), Angelica dahurica (Baizhi), and Morus alba (Sangye) was identified through frequency statistics, association rules, and cluster analysis. GO and KEGG enrichment analyses of the core combination’s targets highlighted mechanisms involving oxidative stress, inflammatory responses, and endocrine regulation, including the TNF and PI3K-Akt signaling pathways. Conclusion: This study successfully employed reverse network pharmacology to predict a core herbal combination for treating PCOS-related infertility. The findings, while requiring experimental validation, offer novel insights for developing therapeutic strategies and provide a foundation for future clinical management.
- Open Access
- 8 October 2025
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 16, 1658812
Modulation of the lncRNA TCONS_00265853-miR-421-5p-CLOCK axis by Ziyin Buyang Formula in polycystic ovarian syndrome with circadian rhythm disruption: an integrated bioinformatics and experimental approach
Background: Polycystic ovarian syndrome (PCOS), a common endocrine disorder in reproductive-aged women, is linked to circadian rhythm disruption, but the molecular mechanisms remain unclear. Dysregulation of the lncRNA TCONS_00265853-miR-421-5p-CLOCK axis may play an important role. Ziyin Buyang Formula (ZYBYF), a Traditional Chinese Medicine (TCM) targeting kidney Yin-Yang balance, shows therapeutic potential, though its mechanism is unclear. This study explores ZYBYF’s role in modulating this axis to improve circadian-disrupted PCOS.Methods: Network pharmacology identified ZYBYF’s bioactive components and targets, integrated with PCOS-associated genes and circadian disruption-related differentially expressed genes (DEGs) from ovarian tissues. A continuous light-induced PCOS rat model (10-week 24-h light exposure) was employed to validate ZYBYF’s effects. Interventions included ZYBYF treatment.Results: Bioinformatics identified 25 intersection targets, with MAPK signaling as the central pathway. In vivo, circadian disruption downregulated lncRNA TCONS_00265853 and CLOCK, elevated miR-421-5p, and hyperactivated MAPK (p-p38, p-ERK1/2, p-JNK), exacerbating ovarian apoptosis (↑BAX, ↓Bcl-2, p < 0.001). ZYBYF restored circadian axis components (↑TCONS_00265853, CLOCK; ↓miR-421-5p), suppressed MAPK activation, and normalized ovarian morphology and hormonal profiles (↓LH, T, ACTH; ↑E2, FSH, p < 0.001). PRKCA expression, a MAPK regulator, was rescued by ZYBYF, counteracting dysregulation of IL1B, VEGFA, and TGFB1.Conclusion: Circadian disruption exacerbates PCOS via the TCONS_00265853-miR-421-5p-CLOCK axis, driving MAPK hyperactivation and ovarian apoptosis. ZYBYF reverses these effects, restoring hormonal balance and follicular dynamics. This study provides mechanistic validation of ZYBYF’s efficacy, positioning it as a promising therapeutic strategy for circadian-disrupted PCOS. These findings suggest that ZYBYF may modulate circadian rhythm–related pathways in PCOS via the lncRNA–miRNA–CLOCK axis, warranting further mechanistic validation.
- 8 October 2025
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 16, 1658812
Open AccessModulation of the lncRNA TCONS_00265853-miR-421-5p-CLOCK axis by Ziyin Buyang Formula in polycystic ovarian syndrome with circadian rhythm disruption: an integrated bioinformatics and experimental approach
Background: Polycystic ovarian syndrome (PCOS), a common endocrine disorder in reproductive-aged women, is linked to circadian rhythm disruption, but the molecular mechanisms remain unclear. Dysregulation of the lncRNA TCONS_00265853-miR-421-5p-CLOCK axis may play an important role. Ziyin Buyang Formula (ZYBYF), a Traditional Chinese Medicine (TCM) targeting kidney Yin-Yang balance, shows therapeutic potential, though its mechanism is unclear. This study explores ZYBYF’s role in modulating this axis to improve circadian-disrupted PCOS.Methods: Network pharmacology identified ZYBYF’s bioactive components and targets, integrated with PCOS-associated genes and circadian disruption-related differentially expressed genes (DEGs) from ovarian tissues. A continuous light-induced PCOS rat model (10-week 24-h light exposure) was employed to validate ZYBYF’s effects. Interventions included ZYBYF treatment.Results: Bioinformatics identified 25 intersection targets, with MAPK signaling as the central pathway. In vivo, circadian disruption downregulated lncRNA TCONS_00265853 and CLOCK, elevated miR-421-5p, and hyperactivated MAPK (p-p38, p-ERK1/2, p-JNK), exacerbating ovarian apoptosis (↑BAX, ↓Bcl-2, p < 0.001). ZYBYF restored circadian axis components (↑TCONS_00265853, CLOCK; ↓miR-421-5p), suppressed MAPK activation, and normalized ovarian morphology and hormonal profiles (↓LH, T, ACTH; ↑E2, FSH, p < 0.001). PRKCA expression, a MAPK regulator, was rescued by ZYBYF, counteracting dysregulation of IL1B, VEGFA, and TGFB1.Conclusion: Circadian disruption exacerbates PCOS via the TCONS_00265853-miR-421-5p-CLOCK axis, driving MAPK hyperactivation and ovarian apoptosis. ZYBYF reverses these effects, restoring hormonal balance and follicular dynamics. This study provides mechanistic validation of ZYBYF’s efficacy, positioning it as a promising therapeutic strategy for circadian-disrupted PCOS. These findings suggest that ZYBYF may modulate circadian rhythm–related pathways in PCOS via the lncRNA–miRNA–CLOCK axis, warranting further mechanistic validation.
- Open Access
A new evaluation system for drug–microbiota interactions
The drug response phenotype is determined by a combination of genetic and environmental factors. The high clinical conversion failure rate of gene‐targeted drugs might be attributed to the lack of emphasis on environmental factors and the inherent individual variability in drug response (IVDR). Current evidence suggests that environmental variables, rather than the disease itself, are the primary determinants of both gut microbiota composition and drug metabolism. Additionally, individual differences in gut microbiota create a unique metabolic environment that influences the in vivo processes underlying drug absorption, distribution, metabolism, and excretion (ADME). Here, we discuss how gut microbiota, shaped by both genetic and environmental factors, affects the host's ADME microenvironment within a new evaluation system for drug–microbiota interactions. Furthermore, we propose a new top‐down research approach to investigate the intricate nature of drug–microbiota interactions in vivo. This approach utilizes germ‐free animal models, providing foundation for the development of a new evaluation system for drug–microbiota interactions.
Open AccessA new evaluation system for drug–microbiota interactions
The drug response phenotype is determined by a combination of genetic and environmental factors. The high clinical conversion failure rate of gene‐targeted drugs might be attributed to the lack of emphasis on environmental factors and the inherent individual variability in drug response (IVDR). Current evidence suggests that environmental variables, rather than the disease itself, are the primary determinants of both gut microbiota composition and drug metabolism. Additionally, individual differences in gut microbiota create a unique metabolic environment that influences the in vivo processes underlying drug absorption, distribution, metabolism, and excretion (ADME). Here, we discuss how gut microbiota, shaped by both genetic and environmental factors, affects the host's ADME microenvironment within a new evaluation system for drug–microbiota interactions. Furthermore, we propose a new top‐down research approach to investigate the intricate nature of drug–microbiota interactions in vivo. This approach utilizes germ‐free animal models, providing foundation for the development of a new evaluation system for drug–microbiota interactions.
- Open Access
- 1 January 2024
- Published by TMR Publishing Group in Traditional Medicine Research
- Vol. 9 (5) , 25
Common key ingredient concluded in Baitouweng decoction, Gegen Qinlian decoction and Shaoyao decoction prevents radiation enteritis by regulating gut microbial network
- 1 January 2024
- Published by TMR Publishing Group in Traditional Medicine Research
- Vol. 9 (5) , 25
Open AccessCommon key ingredient concluded in Baitouweng decoction, Gegen Qinlian decoction and Shaoyao decoction prevents radiation enteritis by regulating gut microbial network